Sample-Size Formula for the Proportional-Hazards Regression Model
From MaRDI portal
Recommendations
- Sample-size formula for clustered survival data using weighted log-rank statistics
- Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
- Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
- Calculating the power or sample size for the logistic and proportional hazards models
- A Sample Size Formula for the Supremum Log‐Rank Statistic
Cited in
(68)- Sample size calculation for the log-rank tests for multi-arm trials with a control
- Sample size calculation for the proportional hazards model with a time-dependent covariate
- Sample size calculation for clustered survival data under subunit randomization
- Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account
- Minimum size survival analysis sampling plans for comparing multiple treatment groups to a single control group
- The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of efficiency and power
- Robust Covariate‐Adjusted Log‐Rank Statistics and Corresponding Sample Size Formula for Recurrent Events Data
- Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
- Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials
- Sample size calculation for a proportional hazards mixture cure model with nonbinary covariates
- Empirical Bayes estimators in hierarchical models with mixture priors
- Proportional hazards model under ranked set sampling scheme using censored data of coronary heart disease
- Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome
- Heterogeneous treatment effects in stratified clinical trials with time‐to‐event endpoints
- Estimation of main effect when covariates have non-proportional hazards
- Sample size calculation for paired survival data: a simulation method
- Calculating the power or sample size for the logistic and proportional hazards models
- A Sample Size Formula for the Supremum Log‐Rank Statistic
- Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time
- A Simulation-Based Evaluation of the Asymptotic Power Formulas for Cox Models in Small Sample Cases
- Sample size formula for general win ratio analysis
- Group sequential testing for cluster randomized trials with time‐to‐event endpoint
- Sample size estimation for cancer randomized trials in the presence of heterogeneous populations
- Expected Precision of Estimation and Probability of Ruling Out a Hypothesis Based on a Confidence Interval
- Design aspects of COVID‐19 treatment trials: Improving probability and time of favorable events
- Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions
- Sample size calculation for the combination test under nonproportional hazards
- Sample size determination in superiority or non-inferiority clinical trials with time-to-event data under exponential, Weibull and Gompertz distributions
- Stratified modestly weighted log‐rank tests in settings with an anticipated delayed separation of survival curves
- Power analysis of approximation methods for parameter estimation in Cox regression model with longitudinal covariate and tied survival times
- Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution
- Two-stage randomized clinical trials with a right-censored endpoint: comparison of frequentist and Bayesian adaptive designs
- Sequential trials in the context of competing risks: concepts and case study, with R and SAS code
- Power analysis for multivariable Cox regression models
- Assessment of effect size and power for survival analysis through a binary surrogate endpoint in clinical trials
- A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models
- Estimation of ascertainment bias and its effect on power in clinical trials with time-to-event outcomes
- Cost-efficient clinical studies with continuous time survival outcomes
- Group sequential design for randomized trials using ``first hitting time model
- Replicability of studies following a dual-criterion design
- Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease
- Exposure density sampling: dynamic matching with respect to a time-dependent exposure
- Sample size calculation for cluster randomization trials with a time-to-event endpoint
- Sample size calculation under nonproportional hazards using average hazard ratios
- A Bayesian adaptive phase III design for multi-arm trials with time-to-event endpoint for nonproportional hazards utilizing the generalized gamma distribution
- Sample size for competing risks survival analysis in fixed and group-sequential designs
- ChatGPT as a tool for biostatisticians: a tutorial on applications, opportunities, and limitations
- Randomized reverse marker strategy design for prospective biomarker validation
- Design and analysis of individually randomized group-treatment trials with time to event outcomes
- Assurance calculations for planning clinical trials with time-to-event outcomes
- Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata
- Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework
- Designing exploratory cancer trials using change in tumour size as primary endpoint
- The use of group sequential designs with common competing risks tests
- Sample size in cluster-randomized trials with time to event as the primary endpoint
- Statistical considerations when using a composite endpoint for comparing treatment groups
- A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution
- Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints
- Optimal survival analyses with prevalent and incident patients
- A bi-endpoint expectation-maximisation algorithm for re-estimating sample size for the time-to-event endpoint under the blind condition
- Auxiliary variable-enriched biomarker-stratified design
- Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks
- An adjusted variance estimator for improvement of test power in the Cox proportional hazards model
- Sample size calculation in the presence of interval censor data using parametric illness-death variance inflation for mixed censoring (PIDV-MC) method
- Blinded-into-unblinded interim analyses for clinical trials with time-to-event endpoints
- Adaptive designs in trials with time-to-event endpoints and covariate adjustment
- Empirical comparison of win ratio and joint frailty models for recurrent event endpoints with applications in oncology and cardiology
- Testing equivalence of survival before but not after end of follow-up
This page was built for publication: Sample-Size Formula for the Proportional-Hazards Regression Model
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3332138)
